WILMINGTON, DE / ACCESSWIRE / October 22, 2024 / Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ GM:EGRX) on behalf of stockholders.
If you purchased or otherwise acquired Eagle Pharmaceuticals shares on or before August 8, 2023 and want to learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-eagle-pharmaceuticals-inc. You may also contact Leah Wihtelin cost free at (516) 693-8926 or by email at lw@rl-legal.com.
About the Investigation:
The investigation concerns whether Eagle Pharmaceuticals and certain of its directors and/or officers issued materially misleading information and/or failed to disclose material information to the investing public. Specifically, the investigation concerns whether Eagle Pharmaceuticals and certain of its directors and/or officers failed to disclose to shareholders that: (i) Eagle Pharmaceuticals was experiencing slower-than-anticipated pull-through from a wholesaler customer predominately due to expiry of inventory; (ii) as a result, Eagle Pharmaceuticals overstated its revenue; and (iii) the Company did not have effective internal controls and procedures over financial reporting for the sales of PEMFEXY, one of Eagle Pharmaceuticals' commercial products.
About Rigrodsky Law:
Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.
Attorney advertising. Prior results do not guarantee a similar outcome.
Contact:
Rigrodsky Law, P.A.
Seth D. Rigrodsky, Esq.
Gina M. Serra, Esq.
Call or Text: (302) 295-5310
Email: info@rl-legal.com
SOURCE: Rigrodsky Law
View the original
press release on accesswire.com
